Loading...

URGN UROGEN PHARMA LTD Product Launches 8-K Filing

RGN

RGN

UROGEN PHARMA LTD

(URGN)

2025 8-K

Show Summary

Show Summary

New Product Launches

Financial Statements

Financial Results

Asset Acquisition

Investor Presentation

Financial Results

Director Resignation

Financial Results

Annual Meeting Approval

Public Offering

Positive Data from Phase 3 ...

Financial Results Announcement

Financial Results Announcement

Presentation at Conference

Notice of ANDA Submission

Agreement and Phase 3 Study

Amendment to Manufacturing ...

Financial Results Announcement

Annual Meeting of Shareholders

Financial Results Announcement

Private Placement

Financial Results Announcement

External Links:

On June 12, 2025, the FDA approved ZUSDURI (mitomycin), a new gel treatment for recurrent low-grade intermediate risk non-muscle invasive bladder cancer, showing a 78% complete response rate at three months, with availability expected around July 1,

AI Assistant

UROGEN PHARMA LTD

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.